newsfilter
← Latest News
Business Wire·

Rockwell Medical Announces Third Quarter 2026 Results

  • Net sales for the third quarter of 2026 reached $19.1 million, a 20% increase compared to the same period in 2025.
  • Gross profit for the third quarter of 2026 rose 37% to $3.1 million, primarily driven by higher sales volumes.
  • The combined annual revenue of Rockwell Medical & Vantive is projected to fall between $400 million & $450 million following their merger.
  • Net sales for the nine months ended September 30, 2026 totaled $54.2 million, representing a 7% increase over the prior year.
  • Gross margin for the three months ended September 30, 2026 improved to 16% from 14% in 2025.
  • Net loss for the three months ended September 30, 2026 was $2.3 million, an increase from $1.8 million in the same period of 2025.
  • Adjusted EBITDA for the three months ended September 30, 2026 was a negative $0.3 million, compared to positive $50,000 in 2025.
  • Cash, cash equivalents, & investments available-for-sale decreased to $22.5 million at September 30, 2026 from $24.8 million at June 30, 2026.
  • Rockwell Medical announced an agreement to acquire Vantive's hemodialysis concentrates, machines, water treatment systems, & manufacturing campus in Italy.
  • Brian Cox was appointed Vice President, Quality & Regulatory Compliance in July 2026.
  • Rockwell Medical was named to the 2026 Fortune Best Workplaces in Manufacturing & Production list for the third consecutive year.